Baseline auxology and responses to growth hormone (GH) treatment in girls with Turner syndrome (TS) from three countries, Japan, Sweden and the United Kingdom, were compared, using data from the Kabi Pharmacia International Growth Study (KEGS). Differences were observed between countries in respect to pretreatment height and height velocity, chronological and bone ages at onset of GH, parental and target heights, body proportions, weight-for-height index, birth weight, and peak GH levels in provocation tests.
Results
Auxology and other parameters before start of GH treatment ( Table 1) 1. Birth weight SDS and birth length SDS.
Swedish girls had significantly greater birth weight SDS than UK girls (P=0.002) and
Japanese girls (P.0.001). Birth length SDS did not differ between countries, although the number of observations from UK and Japan were much reduced compared with Sweden. Doses and regimens of GH The median starting dose of GH was 0.7 U/kg/week in both Sweden and the UK (Fig. 1 ) and 0.5 U/kg/week in Japan, significantly lower (P=0.0001). The current median dose was 0.7 U/kg/week in Sweden and the UK and 0.4 U/kg/week in Japan (P=0.0001). The variability of dosage was greatest in the UK (Fig. 1) . Median weekly frequencies of injections were 7, 6 and 4 at onset of treatment and currently 7, 7 and 6 in Sweden. UK, and Japan respectively.
Response to GH treatment 1. Height SDS (Ranke) (Fig. 2) . Height SDS Values for observed minus predicted height velocity for TS girls from each of the 3 countries were not statistically different (Fig. 5 ). observed with lower and less frequent doses of GH administered in Japan, a wider variation of dose given in the UK (Fig. 1) , and later onset of treatment in Japan.
Response to GH treatment differed accord- 
